Objective: It was hypothesized that in encephalitides with autoantibodies directed to CNS surface antigens an antibody-removing intervention might speed up recovery.
Methods: The outcome of autoimmune encephalitis in 19 patients with antibodies against surface antigens (leucine-rich, glioma inactivated 1 [LGI1], n = 3; contactin-associated protein-2 [CASPR2], n = 4; NMDA receptor [NMDAR], n = 7) and intracellular antigens (glutamic acid decarboxylase [GAD], n = 5) after immunoadsorption in addition to corticosteroid therapy was evaluated retrospectively. Modified Rankin scale (mRS) scores and data on seizures, memory, and antibody titers directly after immunoadsorption (early follow-up) and after a median of 4 months (late follow-up) were compiled.
Results: Immediately after immunoadsorption, 9 of 14 patients with antibodies against LGI1, CASPR2, or NMDAR (64%), but none with GAD antibodies, had improved by at least one mRS point. Five of the 7 patients with LGI1 or CASRP2 antibodies had become seizure-free, and 2 patients with NMDAR antibodies had a memory improvement of more than 1 SD of a normal control population. At late follow-up, 12 of 14 patients with surface antibodies had improved (86%), and none of the patients with GAD antibodies.
Conclusions: It is suggested that addition of immunoadsorption to immunosuppression therapy in patients with surface antibodies may accelerate recovery. This supports the pathogenic role of surface antibodies.
Classification Of Evidence: This study provides Class IV evidence that immunoadsorption combined with immunosuppression therapy is effective in patients with autoimmune encephalitis with surface antibodies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4772911 | PMC |
| http://dx.doi.org/10.1212/NXI.0000000000000207 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
LAG Time in the Era of Immunotherapy-New Molecular Insights Into the Immunosuppression Mechanism of Lymphocyte Activation Gene-3.
Immunol Rev
March 2025
Department of Immunology, Moffitt Cancer Center, Tampa, Florida, USA.
The immune checkpoint receptor lymphocyte activation gene-3 (LAG3) inhibits T-cell activation and was recently validated as a target for cancer immunotherapy. Despite its emergence as a therapeutic target, a lack of molecular-level insight has obscured our understanding of the LAG3 immunosuppression mechanism. This review highlights a series of breakthroughs that have illuminated fundamental aspects of LAG3 molecular biology.
View Article and Find Full Text PDFIgM against Merozoite Surface Protein 1-Block 2 Haplotypes as New Tools for Infections.
J Glob Infect Dis
December 2024
Leônidas and Maria Deane Institute, Oswaldo Cruz Foundation, Manaus, Amazonas State, Brazil.
Introduction: The tools to distinguish relapse from reinfection are needed in malaria-endemic areas. We evaluated seroprevalence against sets of specific peptides to the block 2 region of -merozoite surface protein-1 (PvMSP1) to detect parasite clones.
Methods: We applied amplicon deep sequencing (ADS) of block 2 region of the MSP-1 gene () to determine cocirculating parasite clones within eight -infected individuals.
Extracellular vesicle surface engineering with integrins (ITGAL & ITGB2) to specifically target ICAM-1-expressing endothelial cells.
J Nanobiotechnology
January 2025
Krefting Research Centre, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Extracellular vesicles (EVs) are taken up by most cells, however specific or preferential cell targeting remains a hurdle. This study aims to develop an EV that targets cells involved in inflammation, specifically those expressing intercellular adhesion molecule-1 (ICAM-1). To target these cells, we overexpress the ICAM-1 binding receptor "lymphocyte function-associated antigen-1" (LFA-1) in HEK293F cells, by sequential transfection of plasmids of the two LFA-1 subunits, ITGAL and ITGB2 (CD11a and CD18).
View Article and Find Full Text PDFTargeting antibodies dissociate from drug delivery liposomes during blood circulation.
J Control Release
January 2025
Biotherapeutic Engineering and Drug Targeting, Department of Health Technology, Technical University of Denmark (DTU), Kgs. Lyngby, Denmark. Electronic address:
Despite three decades of intense research, active targeting of liposomes have not been successfully achieved in a clinical setting. A potential explanation is that the clinically used liposomes lose their targeting abilities upon circulation. Here, we investigated if DSPE-PEG anchored antibody-based targeting ligands dissociate from clinically relevant drug delivery liposomes during circulation in mice.
View Article and Find Full Text PDFThe second life for unused COVID-19 vaccines: Towards biosensing application.
Talanta
January 2025
State Research Institute Center for Physical and Technological Sciences, Sauletekio ave. 3, Vilnius, Lithuania; Pharmacy and Pharmacology Center, Faculty of Medicine, Vilnius University, Ciurlionio str. 21, Vilnius, Lithuania. Electronic address:
Many vaccines have been produced during the COVID-19 pandemic. Currently, an increasing number of vaccines have reached an expiration date without being used. Therefore, expired vaccines (EXVAX) based on virus-like particles (VLP) recombinant SARS-CoV2-S protein can be repurposed for biosensing application and provide a use, even though they are past their expiration date for vaccination.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!